Deutsche still bullish on Gilead after Sovaldi launch

|About: Gilead Sciences, Inc. (GILD)|By:, SA News Editor

Deutsche Bank is out with some commentary on Gilead (GILD -0.6%) two weeks into the Sovaldi launch.

IMS data reportedly show 834 new patient starts as of the week ending December 20.

"Assuming new starts increasing to 1000/wk by end of the year and gross to net of 15%, we [calculate] Q4 sales at $61M. If new starts rise to 2000/wk by year end, assuming a gross to net of 15%, we [calculate] Q4 sales at $98M," analyst Robyn Karnauskas notes.

Buy rating maintained.

Price target is $95.